ORGANIC
LETTERS
2010
Vol. 12, No. 7
1492-1495
Rearrangement Strategy for the
Synthesis of 2-Aminoanilines
Achim Porzelle,† Michael D. Woodrow,‡ and Nicholas C. O. Tomkinson*,†
School of Chemistry, Main Building, Cardiff UniVersity, Park Place,
Cardiff, CF10 3AT, U.K., and ImmunoInflammation Centre of Excellence for Drug
DiscoVery, GlaxoSmithKline Medicines Research Centre, SteVenage,
Hertfordshire, SG1 2NY, U.K.
Received January 26, 2010
ABSTRACT
Treatment of N-aryl hydroxylamines with trichloroacetonitrile in the presence of imidazole provides a simple and effective method for the
preparation of synthetically versatile 2-aminoanilines. Reactions proceed in DMF at 40 °C, providing the products in up to 86% isolated yield.
The 2-aminoaniline scaffold has exceptional industrial
significance and is embedded in the structure of a number
of important pharmaceuticals. For example, Nexium, Zyprexa,
and Alphagan P (Figure 1), which contain this group, had
combined worldwide sales in excess of $6.5 billion in 2008.1
Due to the fact that the structure serves as a precursor to a
number of pharmacophores including benzimidazoles,2 1,5-
benzodiazepines,3 quinoxalines,4 benzotriazoles,5 and ben-
zimidazolones,6 among others, simple methods for the
selective introduction of this group have great synthetic
potential.
† Cardiff University.
‡ GlaxoSmithKline, Stevenage.
(1) Drug Top. 2009, 6, 7. For a chemical summary of this information
(2) (a) Bhattacharya, S.; Chaudhuti, P. Curr. Med. Chem. 2008, 15, 1762.
Figure 1. The 2-aminoaniline scaffold in important pharmaceuticals.
(b) Chassaing, C.; Berger, M.; Heckeroth, A.; Ilg, T.; Jaeger, M.; Cern, C.;
Schmid, K.; Uphoff, M. J. Med. Chem. 2008, 51, 1111. (c) Lyaskovskyy,
V. V.; Voitenko, Z. V.; Kovtunenko, V. A. Chem. Heterocycl. Compd. 2007,
43, 253. (d) Spasov, A. A.; Yozhitsa, I. N.; Bugaeva, L. I.; Anisimova,
Methods for the selective amination of monosubstituted
aromatics are scarce, which severely restricts the potential
of the 2-aminoaniline core in drug discovery programs with
V. A. Pharm. Chem. J. 1999, 33, 232.
(3) (a) Zhao, H.-Y.; Liu, G. J. Comb. Chem. 2007, 9, 1164. (b) Horton,
D. A.; Bourne, G. T.; Smythe, M. L. Chem. ReV. 2003, 103, 893. (c) Herpin,
T. F.; Van Kirk, K. G.; Salvino, J. M.; Yu, S. T.; Labaudinie`re, R. F.
J. Comb. Chem. 2000, 2, 513.
(4) (a) Carta, A.; Piras, S.; Loriga, G.; Paglietti, G. Mini ReV. Med. Chem.
2006, 6, 1179. (b) Sato, N. Sci. Synth. 2004, 16, 751.
(6) (a) Kamal, A.; Reddy, K. L.; Devaiah, V.; Shankaraiah, N.; Rao,
M. V. Mini ReV. Med. Chem. 2006, 6, 71. (b) Smith, D. M. In Chemistry
of Heterocyclic Compounds; Preston, P. N., Ed.; Wiley-Interscience:
Chichester, 1981; Vol. 40, p 331.
(5) Craig, P. N. In ComprehensiVe Medicinal Chemistry; Drayton, C. J.,
Ed.; Pergamon Press: New York, 1991; Vol. 8.
10.1021/ol100196a 2010 American Chemical Society
Published on Web 03/03/2010